Deep Dive Ticker Tape
Article published Mar 12, 2026. Prices below use latest available snapshots.
MDT Price Structure
Loading chart…
Loading timeframes…
Conviction: Medium Status: Accumulate — RSI 22.3, price $87.82, extreme oversold, IN entry zone
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟢 RSI 22.3 (computed) — extreme oversold. Price $87.82, -1.3% today, -5.6% 7D, -12.9% 30D. SMA20 ~$95.44 — price -8.0% below SMA. Deep in entry zone. |
| Moat | Moderate-Wide — scale and switching costs |
| Key insight | MDT declined further from $89.89 (03/11) to $87.82 (-2.3%). RSI worsened from 26.7 to 22.3 — now extreme oversold. Price is deep in the $88-94 entry zone flagged earlier, actually near the bottom of it. The PFA franchise (+80% cardiac ablation growth) and MiniMed spinoff catalysts intact. Dividend aristocrat (~3.4% yield). Accumulate in stages. |
Action Matrix
| Action | Level | Why |
|---|---|---|
| Current | 📈 Accumulate | RSI 22.3 extreme oversold, deep in entry zone, dividend aristocrat. |
| Entry Zone | $86 - $94 | Current $87.82 — NEAR BOTTOM OF ZONE |
| Stop-Loss | $79 (-10%) | Below 52-week low ($79.55) |
| Target 1 | $108 (+23%) | Analyst consensus zone |
| Target 2 | $117 (+33%) | All-time high recovery |
Extended analysis
Price Data
| Stock | Price | 1D | 7D | 30D | 3M | RSI | Status | Action |
|---|---|---|---|---|---|---|---|---|
| MDT | $87.82 | -1.3% | -5.6% | -12.9% | -11.4% | 22↓ | 🟢 Extreme Oversold | 📈 Accumulate |
Price vs Last Deep Dive (03/11)
| Metric | 03/11 | 03/12 | Change |
|---|---|---|---|
| Price | $89.89 | $87.82 | -$2.07 (-2.3%) |
| RSI | 26.7 | 22.3 | -4.4 (worsened) |
| SMA20 | ~$96.72 | ~$95.44 | -$1.28 |
| vs SMA | -7.1% | -8.0% | Further below SMA |
Update from 03/11: Selling continues but at extreme oversold levels. RSI now 22.3 — deep in capitulation territory. Price at $87.82 is near the bottom of the entry zone. PFA franchise, MiniMed spinoff, and dividend aristocrat thesis unchanged. Accumulate in stages with $79 hard stop.
Company Overview
One-Liner
Medtronic is the world's largest standalone medical device company — $34B/year spanning cardiovascular, neuroscience, surgical, and diabetes.
Key Segments (Q3 FY2026)
| Segment | Q3 Revenue | Q3 Organic Growth | Key Products |
|---|---|---|---|
| Cardiovascular | $3.457B | +10.6% | PFA/Affera system, TAVR |
| Neuroscience | $2.558B | +2.5% | Spinal fusion, neuro-stim |
| Medical Surgical | $2.173B | +2.7% | Hugo surgical robot |
| Diabetes | $796M | +8.3% | MiniMed (spinning off mid-2026) |
Bull Case
- PFA is a multi-year growth driver — Cardiac Ablation +80% global, +137% US.
- MiniMed spinoff unlocks value — Removes GLP-1 narrative, 100+ bps margin uplift.
- IN entry zone — $87.82 near bottom of $86-94 range.
- Dividend aristocrat — 48 years of increases, ~3.4% yield.
- Cheapest large-cap medtech — P/E ~26x forward vs BSX 57x, SYK 35x.
- RSI 22.3 — Extreme oversold.
Bear Case
- 10-year underperformance — Still below Sept 2021 ATH.
- Hugo is years from revenue — ISRG has 10,763+ systems.
- -5.6% 7D, -12.9% 30D — Active sustained selling pressure.
- Spine is structural drag — Mature, price-deflationary market.
Research Log
| Date | Update |
|---|---|
| 2026-02-22 | Created. Price ~$97.58. RSI ~58. Q3 strongest growth in 10 quarters. |
| 2026-02-26 | $98.61. RSI 36.3. Getting closer to entry zone. |
| 2026-03-11 | FRESH DATA. $89.89 (-8.8% from stale). RSI 26.7. NOW IN entry zone. Accumulate. |
| 2026-03-12 | Continued decline. $87.82 (-2.3%). RSI 22.3 extreme oversold. Near bottom of zone. Accumulate. |
The Gold
Key Discoveries
| Discovery | Implication |
|---|---|
| RSI 22.3 — extreme oversold on world's largest medtech | Rare setup: quality company at capitulation levels |
| -12.9% 30D for a dividend aristocrat | Macro/sector selloff, not company-specific deterioration |
| Near bottom of $86-94 entry zone | Optimal entry area — accumulate with clear $79 stop |
Open Questions
- What drove the continued -5.6% 7D? (Q4 guidance? Sector rotation? Tariff impact on medical devices?)
- Is PFA growth accelerating in Q4?
- What multiple will MiniMed trade at post-spinoff?
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.